Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juliet Penn

Medical Oncology Santa Barbara, CA Medical Doctor

NPI 1215175070 CMS profile 54347

309 W Quinto St, Santa Barbara, CA 93105

Open in the dashboard

General payments

$2,566

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$109,212 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Juliet Penn of Santa Barbara, CA is reported in the CMS Open Payments database as having received $2,566 across 116 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $109,212 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 43rd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82 3
2024 General $243 7
2023 General $380 9
2021 General $37 2
2020 General $253 12
2019 General $1,571 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juliet Penn
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Juliet Penn were reported at $82. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Juliet Penn Medical Oncology median Middle half National median
2019 $1,571 $968 $140–$6,658 $163
2020 $253 $747 $102–$5,891 $114
2021 $37 $430 $50–$4,098 $132
2022 $0 $812 $127–$4,907 $149
2023 $380 $957 $144–$5,248 $160
2024 $243 $1,042 $149–$5,650 $164
2025 $82 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $382 19 payments
  2. Genentech USA, Inc. $186 9 payments
  3. Array BioPharma Inc. $174 11 payments
  4. Novartis Pharmaceuticals Corporation $174 10 payments
  5. Pfizer Inc. $155 9 payments
  6. Merck Sharp & Dohme Corporation $142 8 payments
  7. Aurobindo Pharma USA, Inc. $131 1 payment
  8. Sumitomo Pharma America, Inc. $106 1 payment
  9. AbbVie, Inc. $100 5 payments
  10. Gilead Sciences, Inc. $95 1 payment
  11. Other $922 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,401 107 payments
  2. Education $147 8 payments
  3. Debt forgiveness $17 1 payment
Products named General payments · program years 2019–2025
  1. Mektovi $174 11 payments
  2. Braftovi $174 11 payments
  3. OPDIVO $159 9 payments
  4. REBLOZYL $140 2 payments
  5. Folotyn $131 1 payment
  6. KEYTRUDA $122 7 payments
  7. ORGOVYX $106 1 payment
  8. VENCLEXTA $100 5 payments
  9. Trodelvy $95 1 payment
  10. TECENTRIQ $92 4 payments
  11. Other $2,108 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

233

Median for Medical Oncology: 414

Drug cost

$546,334

Median for Medical Oncology: $849,427

Branded share of claims

39.1%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Verzenio Abemaciclib Brand 18 $299,299
Iclusig Ponatinib Hcl Brand 11 $236,777
Eliquis Apixaban Brand 12 $6,836
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $685
Letrozole Generic 12 $641
Anastrozole Generic 35 $594
Ondansetron Odt Ondansetron Brand 31 $339
Raloxifene Hcl Generic 14 $296
Olanzapine Generic 12 $219
Prednisone Generic 29 $207

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 122 billing codes

Paid by Medicare

$2,406,765

Of which drugs: $2,161,554

Medicare patients

502

Average age 75

Services billed

137,509

318 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 55%
Cancer 50%
Osteoporosis 30%
Ischemic heart disease 27%
Chronic kidney disease 25%
Depression 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 18 6,600 $135,431
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 12 3,450 $117,267
Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg Q5108 Office 16 444 $48,117
Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 Office 12 10,600 $25,130
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 Office 12 10,200 $2,752
Injection, fosaprepitant, 1 mg J1453 Office 24 9,750 $1,073
Injection, carboplatin, 50 mg J9045 Office 13 259 $735
Injection, zoledronic acid, 1 mg J3489 Office 30 161 $733
Injection, palonosetron hcl, 25 mcg J2469 Office 31 730 $475
Infusion, normal saline solution, 250 cc J7050 Office 65 383 $198

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $106
$106 — —
PYRUKYND
  • Agios Pharmaceuticals, Inc. $19
$19 — —
VERZENIO
  • Lilly USA, LLC $19
$19 18 —
RETEVMO
  • Lilly USA, LLC $19
$19 — —
JAYPIRCA
  • Lilly USA, LLC $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record